The anticancer effects of tremelimumab, a CTLA-4-specific human antibody, applied either alone or in combination with H-1PV, were studied by Heinrich et al. [70] n a human in vitro CRC model. The gene discussed is CTLA4; the disease is colorectal carcinoma.